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ess: amund.gulsvik@meSummary About 25 million people are living in the Nordic countries, which include
Denmark, Finland, Iceland, Norway and Sweden. Population demography, growth and
economic status of the countries as well as distribution of known risk factors for
obstructive diseases are of importance for building the evidence base for a health
program. Immigration, changes in lifestyle, increased mobility of the population and
changes of health care services may have an effect on the frequency of the disease.
However, the increase in average age, tobacco smoking and the cumulative exposure
to occupational agents or indoor pollution will cause the greatest impact on the
frequency of obstructive pulmonary disease. This report shows that there is a huge
discrepancy in data availability and reliability and implies an urgent need to collect
accurate and comprehensive vital statistics on obstructive lung diseases in the
Nordic countries.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Information about the comparative magnitude of
various diseases and injuries is a critical input when
building the evidence base for better healthElsevier Ltd. All rights reserve
Indremedisin, Haukeland
orway. Tel.: +4755973242;
d.uib.no (A. Gulsvik).policies and programs. Such information should be
based on a critical evaluation of number and age of
deaths as well as incidence, duration, severity and
costs. Respiratory diseases affect the lives of
people in many different ways. They do not only
represent a major economic burden for all Nordic
countries, but also a major treat to the quality of
life of those diseased. We aim to give a compre-
hensive report on obstructive lung disease in the
Nordic countries as this disease is the majord.
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criteria for success of treatment of obstructive lung
disease may differ among patients, physicians and
health care providers. The main objective of this
paper is to raise public awareness and to inform
decision makers on the high toll paid for obstruc-
tive lung disease in the Nordic countries.Diagnostic criteria
Obstructive lung disease includes asthma and
chronic obstructive pulmonary disease (COPD).
Both conditions show wide spread narrowing of
the bronchial airways, at least on expiration,
causing an increased resistance to airflow. Clinical
staging of these diseases can be useful in manage-
ment decisions, when gauging the effectiveness
of therapy, in identifying groups of patients in
clinical trials, when making prognosis for individual
patients and in predicting medical resource
utilisation.
Asthma is usually defined as a syndrome with
symptoms and clinical signs of intermittent or
reversible obstructive lung disease. Most of the
epidemiological studies use variations of one of two
asthma questions: ‘‘Have you ever had asthma?’’ or
‘‘Have you ever been diagnosed as having asthma
by a doctor?’’ The severity of asthma is classified as
mild intermittent, mild persistent, moderate per-
sistent and severe persistent.1 It has been sug-
gested that severe asthma may be a different
disease compared with mild to moderate asthma.2
The inter- and intra-observer repeatability of
grading disease using symptoms, signs and actual
treatment has not been extensively examined.
COPD is a disease state characterised by not fully
reversible airflow obstruction and defined by
spirometric criteria. The global initiative of COPD3
has recommended a simple cut-off point for disease
with a FEV1/FVC ratio o0.7 after bronchodilata-
tion. The severity of obstruction is defined by a
level of FEV1 in percent predicted. However, there
is neither agreement on what prediction equations
to be used when standardising for age, sex and
body size,4 nor on what type of drug or dosing of
bronchodilatator or length of time after inhalation
to repeat the spirometry measurement. The grad-
ing after bronchodilation, following the GOLDs
classification, is as follows: Very severe disease
with FEV1 below 30% of predicted and severe
disease with FEV1 levels 30–49% of predicted while
moderate disease include FEV1 levels 50–79% of
predicted and mild disease with FEV1 levels of 80%
or higher of predicted. A consequence of the
arbitrary nature of the boundaries selected forseverity classification is that patients close to the
boundaries may be re-classified as more or less
severe if seen on different days. Furthermore, the
concept of severity stages reflecting biological
changes may not be valid for COPD and more
scientific work is needed.
A major strength of the GOLD definition is its
widespread acceptance, simplicity and emphasis on
spirometry for the diagnosis of airflow obstruction.
However, a considerable fraction of the asympto-
matic non-smoking population older than 70 years
has a FEV1/FVC ratio o0.7.5 This may be due to
reduced perception or increased tolerance of
symptoms in the elderly. The current Swedish
guidelines for COPD (www.slmf.se/kol 2005) out-
line how age-related spirometry values can be
included for the diagnosis of COPD. The quality of
life and life prognosis in elderly people with FEV1/
FVCo0.7 have not been thoroughly examined.
Furthermore, confusion remains regarding the
etiologic, pathologic and clinical overlap between
asthma and COPD.Mortality
In the 10th revision of the international classifica-
tion of diseases (ICD), obstructive lung disease
includes categories J 40 to J 46. The mortality data
are in many ways incomplete, but most importantly
is the fact that they do not contain any information
on previous presence of spirometric airway ob-
struction. One must therefore rely on the diagnosis
made by doctors reporting the case. Furthermore,
the quality of the death certificates may have
deteriorated during the last decades in the Nordic
countries as less than 10% of deaths now are
examined post-mortem.
In the Nordic countries altogether 9000 persons
die prematurely every year due to obstructive lung
disease. The death rates vary among the Nordic
countries being 64 per 100,000 in Denmark (3499
deaths in 1998), 39 per 100,000 in Norway (1774
deaths in 1999), 25 per 100,000 in Iceland (61
deaths in 1997), 28 per 100,000 in Sweden (2593
deaths in 1999) and 24 per 100,000 in Finland (1187
deaths in 2000). The overall mortality of obstruc-
tive lung disease has been steadily increasing
during the last 30 years in the Nordic countries.
The ratio between death rates of asthma and COPD
varies greatly being lowest for Denmark and highest
in Sweden. Asthma deaths are rare in children
and young adults with 1–4 deaths per 1 million
inhabitants below 35 years. The male/female ratio
of death rates is highest in Finland and lowest in
Iceland and Denmark. In Denmark, where smoking
ARTICLE IN PRESS
A. Gulsvik et al.S4has been prevalent for decades, mortality rates are
now higher among women than among men in the
younger age groups. Other indices of an increasing
proportion of women with severe obstructive lung
disease are the larger fraction of women than men
in the Swedish Home Oxygen Registry and in the
Norwegian Lung Transplantation Registry.
Patients with obstructive lung disease die more
frequently than patients with non-obstructive lung
disease from smoking related lung cancer, cardio-
vascular and other non-respiratory diseases. Inci-
dent lung cancer is also heavily depending on lung
function impairment. In elderly the mis-classifica-
tion of death certification may underestimate the
impact of COPD more than for conditions such as
cancer or ischaemic heart disease. COPD is often
not included in the vital statistics as it is mentioned
on death certificates more often as a contributory
and not as an underlying cause of death.6 Inclusion
of obstructive lung disease as contributory cause of
deaths increased the death rate by 40% in Norway
(Frostad, 2005, pers. commun.). Formal medical
record review is now needed to definitely deter-
mine the degree to which death certificates under-
estimate the contribution of obstructive lung
disease to mortality.
The Global Burden of Disease Study7 has pro-
jected COPD mortality rates from 1990 to 2020 and
estimated that COPD will account for over 6 million
deaths per year in 2020, which will move COPD
from the sixth- to the third-leading cause of death
worldwide over this period. Overall mortality of
obstructive lung disease will increase in the Nordic
countries due to the increased proportion of
females who smoke as well as to the increasing
average age of the population.Prevalence
Self-reporting respiratory symptoms
Respiratory symptoms are the main reason why
patients with respiratory diseases take contact with
health care professionals. Health-related quality of
life is heavily dependent on the negative impact of
both incidence and persistence of respiratory
symptoms. The causes of the respiratory symptoms
may be due to variable or irreversible airflow
limitation as well as cardio-vascular disease,
anaemia and anxiety. However, the majority of
severe diseases causing respiratory symptoms are
obstructive lung diseases.
The prevalence of a set of 11 respiratory
symptoms (cough, phlegm, wheezing, acute
breathlessness or functional dyspnoe) increased
in a community population aged 15–70 years inNorway from 51% in 19728 to 62% in 1998.9 The most
prevalent symptoms in the Nordic communities are
cough (35%), wheezing (18%), attacks of breath-
lessness (12%) and dyspnoe on moderate level
(13%). The largest increase in symptom frequency
during these 28 years was observed for asthma-like
symptoms and long lasting cough after a cold. In an
11-year community report the cumulative remis-
sion varied from 42% for morning cough to 58% for
chronic cough.10
Physicians or spirometric diagnosis
The prevalence of asthma and COPD has been
distorted by the use of different diagnostic terms
and lung function criteria. Furthermore, a mean-
ingful evaluation of estimates demands knowledge
of age distribution and the smoking habits in
examined populations.
The prevalence of self-reported physicians’
diagnosed asthma in Oslo in 1998 varies in adults
between 5% and 10% and it is higher in those below
30 years compared with those above 50 years.11
The physicians’ diagnosis of asthma has increased
from 1972 to 1998 by a factor of more than 3 in
young adults, but somewhat less in those middle
aged and elderly. The overall increase in respira-
tory symptoms was however considerably less than
for physicians’ diagnosis of disease. The prevalence
of asthma-like symptoms and asthma diagnosis was
similarly in the 1990s for the age group 20–44 years
in Bergen, Gothenburg, Umea˚ and Uppsala, but
lower in Reykjavik.12 The distribution of asthma
severity in a worldwide survey was 44% intermit-
tent, 19% mild persistent, 19% moderate persistent
and 18% severe persistent.13 The size and natural
history of allergic asthma versus non-allergic
asthma has not been extensively studied. However,
a populations based study in Glostrup, Denmark in
1989 and 1998 showed a clear trend of increased
prevalence of allergic asthma defined as shortness
of breath being near grass, trees or flowers;
shortness of breath being near furry animals or
shortness of breath when cleaning rooms or making
bed, or when in bed.14
For the years 1960–2000 the prevalence of COPD
has been estimated in community surveys in several
Nordic countries applying physicians’ use of a
combination of various criteria from spirometry
and symptom questionnaires. These older popula-
tion-based studies indicate that 4–6% of the adult
population suffers from clinically relevant COPD.15
Prevalence increases heavily with age and show
only small differences between men and women.
A spirometry survey in 1987–8816 of a general
population in Western Norway aged 18–73 years and
with 59% ever-smokers showed a prevalence of 6%
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below 0.7. Altogether 12% had a FEV1 less than 80%
of predicted using Norwegian reference values,4
while 4.5% had this ratio as well as FEV1 of less than
80% of predicted. Below the age of 45 years severe
COPD is a rare disease. A spirometry survey in
1996–199717 from the same area with a general
population aged 26–82 years and 62% ever-smokers
gave a prevalence of 9.6% of people with FEV1/FVC
ratio below 0.7. Altogether 18% of this population
had a FEV1 below 80% of predicted, while 6.7% had
a ratio below 0.7 as well as FEV1 of less than 80% of
predicted. Using the severity grading of GOLD
without adrenergic bronchodilation 3% of the
population had a mild stage of COPD, 5.1% a
moderate stage, 1.3% a severe stage while 0.2% of
the total population had a very severe stage of
COPD. Furthermore, a rather large fraction of the
general population (11%) had a FEV1 below 80%
predicted and a FEV1/FVC40.7. After inhalation of
salbutamol the prevalence estimates of COPD
decreased by approximately 30%. The prevalence
of COPD (FEV1/FVCo0.7 after bronchodilatation)
was 10 times higher in the age group 70–82 years
compared to those aged 26–44 years (Fig. 1). Less
than half of the persons with spirometric defined
COPD had a physician’s diagnosis of obstructive lungFigure 1 Prevalence (95% CI) of COPD (FEV1/FVCo0.7)
after bronchodilatation in a general adult population in
south-west Norway.disease. The fraction with self-reported physicians’
diagnosis increased with lung function impairment.Incidence
The incidence of physicians’ diagnosis of asthma
among adults showed a wide range of results and
varies from 0.4 to 11 per 1000 person-years,
indicating that the results are largely depending
on methods used as well as sex and age distribution
of the population under risk.18 In Northern Sweden
the cumulative incidence of physicians’ diagnosed
asthma in a long-term follow-up from 1986 to 1996
in adults aged 37–67 years was 3.2% in men and
4.5% in women.19 Similar incidence estimates,
being 4% in men and 3.5% in women, were observed
for the population of Western Norway aged 15–70
years, who were followed from 1985 to 1996/97.20
In a large prospective study among adults aged
20–44 years followed from 1989–1991 to 1999–2001
the incidence rate of asthma was 2.2 cases per 1000
person-years. The incidence was highly dependent
on the extent to which respiratory symptoms like
wheezing, nocturnal dyspnoea, chest tightness and
cough were excluded from follow up.21 The pooled
estimates of all adult general population cohort
studies in Europe and United States was 5.9 and 4.4
per 1000 person-years in women and men, respec-
tively.22 This review shows that estimates of adult
asthma incidence have tended to be higher in later
studies implying a rise in asthma incidence in adults
within the timeframe of observations. The inci-
dence of physicians’ diagnosed asthma in childhood
is considerably higher in short-term follow-up in
Sweden and has been estimated at 7–10 per 1000
persons-years in the age group 8–10 years.
Longitudinal studies of lung function have shown
that the development of airflow limitation is
heavily depending on smoking habit and dust
exposure as well as ageing. The decline seems to
occur along a slowly accelerating curvy-linear
pathway. In the cohort of the general population
in Western Norway aged 18–74 years the incidence
of COPD was examined from 1987/88 to 1996/97.
Cumulative 9 years incidence of COPD was 6.7%
after bronchodilation.23 Sex did not have an
independent effect of COPD while age was the
most important contributing factor to COPD closely
followed by smoking (Fig. 2) while living in an urban
or rural area had little effect.
The influence of various phenotypes of obstruc-
tive lung disease on survival is so far poorly known.
Why do some COPD patients survive for years with
very low level of lung function while others may
only survive for a few years?
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Figure 2 Cumulative 9 year incidence (95% CI) of COPD (FEV1/FVCo0.7 post-bronchodilation) in a general population
aged 18–74 years.
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Obstructive lung disease is a growing cause of
disability in the Nordic societies. Disability ad-
justed life years are the sums of years lost because
of prematurely death and years lived with disability
adjusted for the severity of the disability. The
utility weight for untreated COPD was initially
estimated by The World Health Organisation and
World Bank to be 0.57 using a person trial off
method.7 However this utility weight must be
heavily depending on the severity of the disease;
being higher in patients with a mild disease
compared with patients with a severe disease.
Perfect health is weighted as 1 and death as 0.
Further data on health status and quality of life in
patients with variable and irreversible obstructive
lung disease is highly necessary. The Euroquale
scale (EQ-5D) is due to its simplicity recommended
to use because it is possible to compare quality of
life in patients with COPD with quality of life in
patients with other diseases.24
Estimated disability adjusted life years (DALYs)
lost due to COPD was 2.3 million DALYs in 1990 in
countries with established market economy. Giventhe size of the population in the Nordic countries a
crude estimate of DALYs lost in the Nordic countries
due to COPD will thus be 69,000 per years.
According to the projection of the 1990 WHO’s
Global Burden of Disease Study, COPD will rank 5th
in 2020 responsible for 4% of total DALYs lost. Only
ischaemic heart disease, major depression, traffic
accidents and cerebro-vascular disease will cause a
greater burden.Comorbidites
The health care workers of respiratory medicine
have tended to neglect the contributions that
comorbid conditions have on outcome of COPD. In
fact, randomised clinical trials of new treatments
for COPD usually exclude persons with serious
comorbid conditions. Mapel et al.25 found in
patients in a health management organisation that
COPD cases had almost two times higher prevalence
of congestive heart disease, localised cancer,
ulcers, gastritis and depression compared with
non-COPD cases. Hospitalisation and out patient
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than in age and sex adjusted controls without
COPD. When including COPD patients more atten-
tion should be paid also to comorbide diseases in
clinical trials and research.Economic burden
Cost of illnesses provides insight into the economic
impact of a disease. The direct cost is the value of
health care resources devoted to diagnosis and
medical management of the disease. Indirect costs
reflect the monetary consequences of disability,
missed work and school, premature mortality, and
caregiver or family costs resulting from the illness.
It has been estimated that for the total financial
burden of lung diseases in Europe is 17% due to
inpatient care, 9% due to ambulatory care, 7% due
to drug supply, 20% due to premature mortality and
rehabilitation and 47% due to lost working days.18
In the Nordic countries the health services are a
public matter. It is provided in accordance with
legalisation and they are largely financed by public
spending or through compulsory health insurance
schemes. For many years there has been a trend in
the Nordic countries to close down small hospitals.
Resources have been concentrated in fewer units.
There are, however, large differences in the use of
health personnel in the Nordic countries, both in
total and for the different categories of health
personnel.
Asthma and COPD accounted each for about SEK
3 billion in Sweden in 1991, together roughly 2% of
the economic cost of all diseases. The direct cost of
COPD related to medical care in Sweden was
estimated to be 1 billion SEK in 1991. The
estimated indirect cost of COPD was an additional
1.7 billion SEK.26 More recent estimates27 from
Sweden have given figures which are almost three
times larger being 9.1 billion SEK for COPD alone.
Currently, COPD is a more costly disease than
asthma. The health care costs per patient per year
with COPD were estimated for severe disease to be
three times as high as costs for moderate disease
and more than ten times as high as for mild disease.
Using the classification of severity recommended by
the British Thoracic Society, subjects with mild
disease (83% of all cases) account for 29% of the
costs while subjects with moderate disease (13%
of all cases) account for 41% of the total costs. The
subjects with severe disease (o4%) account for
the remaining 30% of the total costs. In Sweden
the drug and primary care costs due to asthma and
COPD during the last decades have increased
considerable since 1999. Hospital costs due toasthma have decreased while COPD costs have
increased.28
Exacerbations are the key drivers in the costs of
COPD. Precise estimates for overall frequency of
resource-defined exacerbation by severity of dis-
ease are so far unknown for the Nordic countries.
However, subjects with lower lung function experi-
enced more often and more severe exacerbations
than those with moderate reduced lung function.
The average health care costs per exacerbation
were SEK 120 for a mild (self-managed exacerba-
tion), SEK 2.111 for a moderate (health care visit)
and SEK 21.852 for a severe (hospitalisation)
exacerbation.29 Exacerbations account for 35–45%
of the total per capita health care costs for COPD in
Sweden. Ministry of Social Affairs and Health in
Finland30 has estimated that treatment periods and
hospitalisation days for COPD may increase by 2010
by up to 55% for men and 24% for women as
compared with the situation in the 1990s.
While patients and physicians make decisions for
the good of individuals, health care payers focus on
decision making on the population level. Outcome
measures of interest to health care payers making
decisions on treatment approaches within the area
of obstructive lung disease include improvement in
FEV1, improvement in symptom-free days, reduc-
tion in exacerbations and improvement in health-
related quality of life. Measures that combine costs
and utility measures such as EQ-5D and costs per
exacerbation avoided are of particular interest for
the health care payers and should be studied more
extensively in the Nordic countries by scientific
teams of economists and physicians.
Physicians
The total number of active physicians in the Nordic
countries in 2001 varied between 940 (Iceland) and
25,000 (Sweden) and capita per active physician
being lowest for Sweden (307) and highest in
Finland (350).
Precise data on general practice consultations
per 100,000 inhabitants for obstructive lung dis-
eases is lacking. However, estimates for COPD
consultations in Copenhagen was 1000–1500 per
100,000 inhabitants per year which is much lower
than in United Kingdom.31 Patients with mild or
moderate obstructive lung disease seek outpatient
medical attention because of cough and production
of mucus, breathlessness or respiratory infections.
Population (in thousands) per active chest phy-
sician in the Nordic countries is as follows: Denmark
59, Finland 26, Iceland 13, Norway 21 and Sweden
21. Patients with severe and very severe COPD in
the Nordic countries requires continuously monitor-
ing and medications by specialists. The number of
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next few years due to expected retirement, which
will not be compensated by the specialist currently
in training. Furthermore, the gender distribution,
changing activities considering clinical work versus
free time may reduce the available time for
patient’s work in hospitals for the future.
Hospitals beds
The number of beds for each patient group is
calculated by dividing hospitalisation days by 365
days. Hospital admissions may reflect the combined
impact of prevalence, severity and quality of care.
In Norway more than 20% of all hospital admissions
of children are due to acute asthma. A steady
increase in hospitalisation rates was observed
particulary among children below the age of 5
years. However, from 1990 to 1995 re-admissions
has decreased markedly32 probably related to the
marked increased use of inhaled steroids.
The estimates based on Finnish national disease-
specified and hospital registries warned on the huge
increase on hospitalisation due to COPD.33 In 1998,
Ministry of Health and Social Affairs in Finland
launched the National Programme for Prevention
and Treatment for COPD to stop the predicted huge
increase of COPD patients and their increased use
of medical services.34
Altogether 300–400 hospitalisations due to ob-
structive lung diseases per year per 100,000
inhabitants have been estimated for Western Nor-
way.35 For those older than 60 years of age, the
rates were more than 1000 per 100,000 inhabitants.
The average length of a hospital stay in 1997 was
approximately 9 days for patients with COPD and 5
days for patients with asthma. It has declined
further during the later years. Admission rates have
increased more in women than in men and in the
elderly compared with young. Hospitalisation rates
for obstructive lung disease are also dependent on
the organisation of emergency units and home care
as well as the availability of hospital beds.
Hospitalisations due to exacerbations of obstruc-
tive lung disease are serious events with 25%
probability for death within 2 years36 and 60%
probability of re-hospitalisation within 12
months.37
For hospital beds in general the number of beds
for admissions with obstructive lung disease has
been drastically declining to 613 beds in Finland
and 460 beds in Sweden in 1998. At the same time
hospitalisation periods have been markedly shor-
tened and it may be further shortened in the
future. The patient’s general practitioner or nurse
in primary health care may also help more in the
future by active participating in the process anddecision-making when the patients are discharged
from hospitals. Furthermore, we must re-consider
novel alternatives like home hospitals. Whether
this is more cost-effective than hospital admissions
have to be shown.
Drugs
The sales in the Nordic countries of medical
products to the respiratory systems cost about
800 million h in 2000. Approximately 2/3 of the cost
is due to drugs for obstructive airway diseases.
Expenditure per capita for respiratory system drugs
is 45h in Iceland, 43h in Norway, 34h in Finland, 33h
in Denmark and 26h in Sweden. The costs of drugs
have since the 1980 increased considerably for both
asthma and COPD.
However, the overall use of defined daily doses of
obstructive lung disease drugs per 1000 inhabitants
have not changed much from 1999 to 2003 in the
Nordic countries. The sales of combinations of
inhaled steroids and long lasting adrenergic b2
agonists have increased dramatically since it was
introduced in 1999. In 2003 the sales of xanthines
have declined to approximately a fourth of what it
was used in 1985 while the sales of anti-leukotriene
drugs and long acting cholinergic is slowly increas-
ing. When the use of anti-asthmatic drugs is
properly targeted in asthma and COPD treatment
with good patient adherence, it will decrease both
severity and exacerbation rates of obstructive lung
disease, and thereby cost effective.Conclusions
The increased burden of obstructive lung disease
has to come to the awareness of the public,
governments and health authorities in the Nordic
countries. Obstructive lung disease is the only
leading cause of death that is increasing in
prevalence worldwide.15 The Nordic countries
should establish national management strategies
including patient registries for obstructive lung
diseases as a research tool to prevent the disease
and to improve the care for this very large
population of patients. Health professionals should
be more active partners to implement strategies
for effective prevention, diagnosis and treatment
of these disabling and life-threatening diseases.References
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